INSECTICIDES (INDIA) LTD. - 532851 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
This is to inform you that our Company's Earning call to be held on Friday, February 11, 2022 from 16:00 IST to discuss the Company's 3QFY22 Financial results. The Standalone & Consolidated Unaudited Financial results of the Company for the third quarter & nine months ended December 31, 2021 to be announced on February 10, 2022. INSECTICIDES (INDIA) LTD. - 532851 - Board Meeting Intimation for To Consider And Approve Un-Audited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended December 31, 2021
INSECTICIDES (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2022 ,inter alia, to consider and approve to consider and approve Un-audited Standalone and Consolidated financial results for the quarter and nine months ended December 31, 2021. INSECTICIDES (INDIA) LTD. - 532851 - Intimation To Shareholders Holding Shares In Physical Mode
Please take note that pursuant to the SEBI Circular No. SEBI/HO/MIRSD/MIRSD RTAMB/P/CIR/2021/655 dated November 03rd, 2021, the Company is sending intimation to the shareholders holding shares in physical form requesting them to update/submit the details in the requisite forms for updating the PAN, K YC details and Nomination details to the Registrar and Share Transfer Agent of the Company.
Insecticides India Q3 PAT seen up 256.2% YoY to Rs 22 cr: Sharekhan
Net Sales are expected to increase by 5 percent Y-o-Y (down 29.2 percent Q-o-Q) to Rs 314 crore, according to Sharekhan. INSECTICIDES (INDIA) LTD. - 532851 - Shareholding for the Period Ended December 31, 2021
Insecticides (India) Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here INSECTICIDES (INDIA) LTD. - 532851 - Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Sandeep KumarDesignation :- Company Secretary and Compliance Officer INSECTICIDES (INDIA) LTD. - 532851 - Closure of Trading Window
It is informed that the ''trading window' for dealing in securities of Insecticides (India) Limited shall remain closed from January 01, 2022 till the end of 48 hours after declaration of financial results for the third quarter ended on December 31, 2021 are made public. INSECTICIDES (INDIA) LTD. - 532851 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
We wish to inform you that pursuant to Regulation 30 read with Schedule II (Part A) (15) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 the management of the Company shall meet with the Investors / Analyst virtually on December 22nd, 2021. Insecticides (India) Ltd - 532851 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
In continuation of our earlier letter No. Ref: IIL/SE/2021/1211/02 dated November 12, 2021, in regard to the Company''s earning call which was held on Tuesday, November 16, 2021 to discuss the Company''s 2QFY22 financial results, we hereby submitting the Transcript. Q2FY22 Quarterly Result Announced for Insecticides (India) Ltd.
Highlights: Q2 FY22 v/s Q2 FY21: Revenue from Operations has marginally degrown from Rs. 4558.48 Mn in Q2 FY21 to Rs. 4439.39 Mn in Q2 FY22 mainly due to decline in Sale of Branded products because of unfavourable monsoons in this year. The EBITDA increased by 11.12% from Rs. 577.49 Mn in Q2 FY 21 to Rs. 641.69 Mn in Q2 FY22 mainly due to the change in product mix where there was an increase in share of Maharatna products sale thereby giving higher margins. EBITDA margins increased to 14.45% in Q2 FY22 from 12.67% in Q2 FY21. Net profit increased by 0.87% from Rs. 414.01 Mn in Q2 FY21 to Rs. 417.62 in Q2 FY22 PAT margins increased to 9.53% in Q2 FY22 from 9.08% in Q2 FY21. H1 FY22 v/s H1 FY21: Revenue from Operation recorded a growth by 5.40% from Rs. 8654.47 Mn in H1 FY21 to Rs. 9122 Mn in H1 FY22 mainly driven by an increase in sale of B2B products and Exports. The EBITDA increased by 9.63% from Rs. 1069.56 Mn in H1 FY21 to Rs. 1172.51 Mn in H1 FY22 and a gain in the EBITDA margins from 12.36% in H1 FY21 to 12.85% in H1 FY22. Net profit stood at Rs. 764.75 Mn in H1 FY22, compared to Rs. 654.82 Mn in H1 FY21 recorded a growth of 16.79% Total Fixed Asset grew by 10.34% from Rs. 3228.33 Mn in H1 FY21 to Rs. 3562.26 Mn in H1 FY22 Current Asset stood at Rs. 10445.40 Mn in H1 FY22, compared to Rs. 9593.51 Mn in H1 FY21 Long term borrowing stood at Rs. 18.61 Mn in H1 FY22, compared to Rs. 14.42 Mn in H1 FY21 and Short-term borrowing at Rs. 1908.90 Mn in H1 FY22, compared to Rs. 559.77 Mn in H1 FY21 Inventory Holding Period has increased to 153 days in H1 FY 22 compared to 135 days in H1 FY 21 increased inventory holding of raw materials by the management due to production issues in China. Working Capital Cycle has increased to 160 days in H1 FY 22 compared to 115 days in H1 FY 21 due to increased inventory holding. Debt Equity ratio has increased marginally, to 0.23 in H1 FY 22 compared to 0.07 in H1 FY 21 Commenting on the performance, Mr. Rajesh Aggarwal, Managing Director, said: “The second quarter witnessed several challenges due to the 2nd wave of Covid-19 and flood like situation in various states due to heavy rainfall. The Pandemic has resulted in extended lockdowns, slowing down of economic activity and several logistic issues. The Agro sector was slightly less impacted and currently we are seeing demand picking up with easing of restrictions and relaxations in lockdown at several places. The Company has recorded revenue from operations of Rs. 4439 Mn in Q2 FY22, and Rs. 9122 Mn on a half yearly basis, representing a growth of 5.40% on a half yearly basis. Revenue growth was driven by all segments except Branded Products (other than Maharatna category). The Maharatna category of branded products grew by 17% from Rs 1793.5 Mn in Q2 FY21 to Rs 2099 Mn in Q2 FY22. The revenue of branded products other than the Maharatna Range fell by 32% from Rs 1559.3 Mn in Q2 FY21 to Rs. 1062 Mn in Q2 FY22 mainly due to change in product mix, increased focus on Maharatna range of products under the tail cutting policy of the company. The exports grew by 28.76% and institutional sales grew by 3% on a quarterly basis. We are happy to state that we have achieved an export sale of Rs 563 MN on a half yearly basis in FY22 vs our total export turnover of Rs 610 MN on a full year basis of FY 21. The Company delivered EBITDA of Rs. 641.69 Mn in Q2 FY21, with margins of 14.45%. Net profit for the quarter was Rs. 423 Mn, with margins of 9.53%. The company also received registration under section 9 (3) of the Indian Patent Act for two technical in the current quarter. The growth was minutely impacted due to lockdowns and slowing of economic activity. Despite challenges, we were successful in maintaining an adequate level of engagements with our customers and other stakeholders via digital channels. We are also trying to remedy our dependency on China for raw materials; firstly by planning to launch Japanese products and technicals through our in-licensing partners. Secondly, keeping in mind our government’s Make-In-India policy and economies of backward integration we have invested substantially in enabling our plants, like Dahej & Rajasthan; to produce the raw materials & technicals required for our products. We are proud to state that we produce around 20 technicals which are used in 30-40 of our formulations and plan to increase this number in the coming years. We also plan to ultimately export our in-house technicals so as to become less reliant on imports and increase our export share. Lastly, the management was able to successfully envisage the issue of price increase in raw materials due to production abruptions in China and hasthus, put in a plan to mitigate it by increasing level of inventory holding to ensure uninterrupted production in our plants for the fiscal year 21-22. The company further plans to remedy this by increasing the production of premium selling products where the increase in raw material prices is relatively moderate. We do not anticipate any adverse impact of this event on our margins, rather we foresee a positive growth in our margins during FY22. Thus, the issue of raw material price increase is backed by a well-planned pricing and production strategy to ensure that the plans & targets for FY 22 are met and further help us to reduce our dependency on China. With the re-opening of the economy post the second national lockdown, we expect lot of new product registrations to be finalized in the upcoming quarters. Our exports of Rs. 177.52 MN in Q2 FY 2022, and Rs 563.83 MN till end of H1 FY 22, is in line with our export target of 1000 MN export sales for FY 22. Management team remains committed to continue its efforts in launching many new products this year, improve profitability of the business through expanding its backward integration capabilities and take all other strategic measures so as to increase the longterm value for all its stakeholders.” Result PDF